✦ LIBER ✦

S2071 In HIV-HCV Co-Infected Patients with HCV Genotype 2 or 3 Infection a 6-Month Treatment with Peginterferon Alpha Plus Ribavirin Has the Same Efficacy As in Mono-Infected Patients

✍ Scribed by Gonvers, Jean-Jacques; Heim, Markus H.; Cavassini, Matthias; Müllhaupt, Beat; Genné, Daniel; Bernasconi, Enos; Pantaleo, Giuseppe; Oneta, Carl M.

Book ID: 122085472
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 52 KB
Volume: 136
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(09)61486-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Impact of peginterferon alpha-2b and rib

Impact of peginterferon alpha-2b and ribavirin treatment on liver tissue in patients with HCV or HCV–HIV co-infection

✍ Rui Sarmento-Castro; Ana Horta; Olga Vasconcelos; Helena Coelho; Josefina Mendez 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 205 KB

Peginterferon alfa-2b plus ribavirin for

Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3

✍ Stefan Zeuzem; Rolf Hultcrantz; Marc Bourliere; Tobias Goeser; Patrick Marcellin 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 220 KB

Which is the real efficacy of pegylated

Which is the real efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in HCV infected patients with advanced fibrosis?

✍ Adriano M. Pellicelli; Mario Romano; Paolo Guarascio; Pascal Vignally 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 211 KB

P.411 The impact of age on sustained vir

P.411 The impact of age on sustained virological response in genotype 1 HIV-HCV co-infected patients receiving peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®): AIDS PEGASYS ribavirin co-infection trial (APRICOT)

✍ J. Rockstroh; F.J. Torriani; M. Rodriguez Torres; E. Lissen; A. Lazzarin; J. De 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 274 KB

697 AN OPEN-LABEL, COMPARATIVE, MULTICEN

697 AN OPEN-LABEL, COMPARATIVE, MULTICENTRE STUDY OF PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN IN THE TREATMENT OF PATIENTS CHRONICALLY INFECTED WITH HCV/HBV OR HCV ALONE

✍ C.-J. Liu; W.-L. Chuang; C.-M. Lee; S.-S. Wu; L.-Y. Liao; H.-T. Kuo; Y.-C. Chao; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 52 KB

328 Comparison of 48 or 72 weeks of trea

328 Comparison of 48 or 72 weeks of treatment with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C infected with HCV genotype 1

✍ Thomas Berg; M. Von Wagner; H. Hinrichsen; T. Heintges; P. Buggisch; T. Goeser; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB